Osteogenesis imperfecta: Anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 3, 2006, Pages 332-339

  Vallo, Alfredo ^a   Rodriguez Leyva, Francisco ^b   Rodríguez Soriano, Juan ^a,c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE PEDIATRÍA   (Mexico)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

Bisphosphonates; Bone mineral density; Growth; Osteogenesis imperfecta; Pamidronate

Indexed keywords

CALCIUM; PAMIDRONIC ACID; PARACETAMOL; PHOSPHATE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; ANTHROPOMETRY; APPETITE DISORDER; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCULATION; CATCH UP GROWTH; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FEVER; FLU LIKE SYNDROME; FRACTURE; GROWTH; GROWTH RATE; HUMAN; INCIDENCE; INFANT; IRRITABILITY; LONG TERM CARE; LUMBAR SPINE; MAINTENANCE THERAPY; MALE; MINERAL METABOLISM; MYALGIA; OSTEOGENESIS IMPERFECTA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; URINARY EXCRETION;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BODY WEIGHTS AND MEASURES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MAGNESIUM; MALE; OSTEOGENESIS IMPERFECTA; PHOSPHATES;

EID: 33644582597     PISSN: 08035253     EISSN: 15023869     Source Type: Journal    
DOI: 10.1080/08035250500434785     Document Type: Article

References (34)

1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-16.
2. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339: 947-52.
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocrin Rev 1998;19:80-100.
4. Astrom A, Soderhall S. Beneficial effect of long term intravenous bisphophonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86:356-64.
5. Giraud F, Meunier FJ. Effect of intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. Joint Bone Spine 2002;69:486-90.
6. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003;111: 573-8.
7. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Clouthier S, Rabzel M, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003;111:e601-3.
8. Dimeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment in children under 36 months of age with osteogenesis imperfecta. Bone 2004;35:1038-45.
9. Zeiltin L, Rauch F, Plotkin H, Glorieux FX. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics 2003; 111:1030-6.
10. Shaw NJ, Bovin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000;83:143-5.
11. Hernández M, Castellet J, Narvaiza JL, Rincón JM, Ruiz E, Sánchez E, et al. Growth graphics and tables. Madrid: Garci Ed.; 1988.
12. Schönau E. The peak bone mass concept: is it still relevant? Pediatr Nephrol 2004;19:825-31.
13. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone morphometry data. J Bone Miner Res 1992;7:137-45.
14. Olsen IE, Ittenbach RF, Rovner AJ, Leonard MB, Mulberg AE, Stallings VA, et al. Deficits in size-adjusted bone mass in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 2005;40:76-82.
15. Bachrach LK, Hastie T, Wang M-C, Narasimhan B, Marcus R. Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab 1999;84:4702-12.
16. Ellis KJ, Shypailo RJ, Hardin DS, Perez MD, Motil KJ, Wong WW, et al. Z score prediction model for assessment of bone mineral content in pediatric patients. J Bone Miner Res 2001; 16:1658-64.
17. Plotkin HG, Rauch F, Bishop J, Monpetit K, Rick-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50.
18. Vieira NE, Goans RE, Weiss GH, Hopkins E, Marini JC, Yergey AL. Calcium kinetics in children with osteogenesis imperfecta, types III and IV: pre- and post-growth hormone therapy. Calcif Tissue Int 67:97-100.
19. Bone 2000;25:501-5.
20. Marini JC, Hopkins E, Glorieux FX, Chrousos GP, Reynolds JC, Gundberg CM, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type 1 procollagen. J Bone Miner Res 2003;18:237-43.
21. Noda H, Onishi H, Saitoh K, Nakajima H. Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2002;15: 217-8.
22. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 2002;110:1239-41.
23. Rauch F, Travers R, Plotkin H, Glorieux FX. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110:1293-9.
24. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralization and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160: 641-4.
25. Rauch F, Plotkin H, Zeitlin L, Glorieux FX. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003;18:610-4.
26. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta. J Pediatr Endocrinol Metab 2004;17:1511-7.
27. Rauch F, Plotkin H, Travers R, Zeitklin L, Glorieux FX. Osteogenesis imperfecta types I, III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-92.
28. Chines A, Boniface A, McAlister W, Whyte MP. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr 1995;119:51-7.
29. Vezzoli G, Soldati L, Arcidiacono T, Terranegra A, Biasion R, Russo CR, et al. Urinary calcium as a determinant of bone mineral density in elderly men participating in the In-CHIANTI study. Kidney Int 2005;67:2006-14.
30. Freundlich M, Alonzo F, Bellorin-Font E, Weisinger JR. Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 2002;17:1396-401.
31. Rodríguez-Soriano J, Vallo A, Aguirre M. Bone mineral density and bone turnover in patients with Bartter syndrome. Pediatr Nephrol 2005;20:1120-5.
32. Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine 2004;71:51-5.
33. Lee T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 2004; 13:417-22.
34. Schiavi S, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004;65:1-14.